• Welcome to Phoenix Rising!

    Created in 2008, Phoenix Rising is the largest and oldest forum dedicated to furthering the understanding of and finding treatments for complex chronic illnesses such as chronic fatigue syndrome (ME/CFS), fibromyalgia (FM), long COVID, postural orthostatic tachycardia syndrome (POTS), mast cell activation syndrome (MCAS), and allied diseases.

    To become a member, simply click the Register button at the top right.

Dr. Apparao Peddapalli An inflammatory approach

Rufous McKinney

Senior Member
Messages
13,249
the web site mentions anti-inflammatory theory, and mentions this existing pharmaceutical: canakinumab

But its not clear if he is using that substance.

Wikipedia says:

Those treated in CANTOS (trials) had a 15% reduction in deaths from heart attacks, stroke and cardiovascular disease combined. However, there were serious side-effects, and no statistically significant overall survival benefit. Nonetheless, David Goff, director of the division of cardiovascular sciences at the National Heart, Lung and Blood Institute feels the "public health impact potential is really substantial,” and estimates that in the United States 3 million people might benefit from canakinumab.[13]